PRMT5 and neoplasm: These mechanisms highlight how methylation-mediated regulation of signaling and immune checkpoints promotes an immunosuppressive tumor microenvironment, identifying methyltransferases such as PRMT5 as promising therapeutic targets to improve CRC outcomes.